

**Question for written answer E-001203/2025
to the Commission**
Rule 144
Wouter Beke (PPE), Liesbet Sommen (PPE)

Subject: EU action to accelerate biotech solutions for autoimmune disease patients

Over the past decade, autoimmune diseases have surged across Europe, driving social, economic and healthcare costs to over EUR 50 billion¹. The upcoming EU biotech act is a top political priority, aimed at harnessing European biotech innovation to enable quicker and more effective diagnoses and treatments. This bold initiative seeks to turn the tide against autoimmune diseases, a mounting challenge for public health.

1. What specific measures is the Commission considering to help boost collaboration between biotech companies, academia and healthcare providers, and in turn to accelerate the development of innovative diagnostics and treatments for autoimmune disease patients?
2. How will the new biotech act enhance regulatory pathways for innovative biotech therapies, ensuring both faster deployment and the continued prioritisation of patient safety?
3. How does the Commission plan to encourage ongoing research and development for multiple indications of both current and future products?

Submitted: 20.3.2025

¹ Greiner, W., Patel, K., Crossman-Barnes, C. J., Rye-Andersen, T. V., Hvid, C., & Vandebrouck, T. 'High-Expenditure Disease in the EU-28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes?'. *Pharmacoeconomics – open*, 5(3), 385–396. (2021) <https://doi.org/10.1007/s41669-020-00253-4>.